Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Delcath Systems, known by the stock symbol DCTH, announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference, offering on-demand access to their presentation. The company focuses on interventional oncology, specifically targeting rare liver cancers with its investigational product, HEPZATO KIT. This product seeks to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects. While HEPZATO KIT is not FDA-approved yet, its European counterpart, CHEMOSAT, has been utilized at major medical centers.

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

The presentation is now available “on-demand” by visiting https://hcwevents.com/bioconnect/#

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Safe Harbor / Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company’s clinical trials, including without limitation the mOM and ICC clinical trial programs, our determination whether to continue the ICC clinical trial program or to focus on other alternative indications, and timely monitoring and treatment of patients in the global Phase 3 mOM clinical trial and the impact of the COVID-19 pandemic on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; approval of Individual Funding Requests for reimbursement of the CHEMOSAT product; the impact, if any, of ZE reimbursement on potential CHEMOSAT product use and sales in Germany; clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK; the Company’s ability to successfully commercialize the HEPZATO KIT/CHEMOSAT system and the potential of the HEPZATO KIT/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for the CHEMOSAT system in various markets; approval of the current or future HEPZATO KIT/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets; actions by the FDA or foreign regulatory agencies; the Company’s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company’s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara 
(646)-755-7412 
james@haydenir.com

FAQ

What did Delcath Systems announce on January 11, 2021 related to DCTH?

Delcath Systems announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

Where can I access the Delcath presentation from the BIOCONNECT 2021 Conference?

The presentation from Delcath Systems is available on-demand at the H.C. Wainwright BIOCONNECT website.

What is the focus of Delcath Systems as a company identified by DCTH?

Delcath Systems focuses on interventional oncology, specifically treating primary and metastatic liver cancers.

What is the investigational product of Delcath Systems mentioned in the press release?

The investigational product is the HEPZATO KIT, designed for high-dose chemotherapy delivery to the liver.

Is the HEPZATO KIT approved by the FDA for use in the U.S.?

No, the HEPZATO KIT has not yet received FDA approval for sale in the U.S.

What is the trade name for Delcath's system in Europe?

In Europe, the system is marketed under the trade name CHEMOSAT.